T he contraction of cardiac muscle is initiated by the influx of Ca 2ϩ through voltage-sensitive Ca 2ϩ channels. Some of the Ca 2ϩ entering the cell binds to Ca 2ϩ release channels (ryanodine receptors) on the sarcoplasmic reticulum (SR) and triggers a release of Ca 2ϩ from the SR. After the subsequent contraction, Ca 2ϩ must be removed from the myoplasm to facilitate relaxation. Most Ca 2ϩ is pumped back into the SR, but a significant fraction is extruded from the cell by the Na ϩ -Ca 2ϩ exchanger. In the steady state, the amount of Ca 2ϩ leaving the cell via the exchanger equals the amount of Ca 2ϩ that enters through Ca 2ϩ channels. 1 exchanger in excitation-contraction coupling arises in pathophysiological situations. In many models of hypertrophy and heart failure, for example, Na ϩ -Ca 2ϩ exchange activity is upregulated. Additionally, other alterations in heart failure (prolonged action potential, increased Na ϩ i ) might increase the importance of the exchanger as a Ca 2ϩ influx pathway. Indeed, the results of several studies have implicated the importance of reverse Na ϩ -Ca 2ϩ exchange in the maintenance of contractility during heart failure. Na ϩ -Ca 2ϩ exchange has also been implicated in the generation of arrhythmias during heart failure, and it remains unclear whether an upregulation of the exchanger is a beneficial adaptation. 3, 4 Two studies in this issue of Circulation Research provide new tools and new information on these issues. A clever, and technically demanding, approach was used by Weber et al 5 ? Despite these qualifications, a new standard has been set for understanding the action of Na ϩ -Ca 2ϩ exchange during an action potential. Future work should not ignore the implications of this study.
Importantly, the approach of Weber et al 5 can now be directly applied to pathophysiological situations. Will the altered conditions present in heart failure bestow the Na ϩ -Ca 2ϩ exchanger with increased importance as a trigger mechanism? We will stay tuned for the answer.
A second study on Na ϩ -Ca 2ϩ exchange by Müller et al, 6 also in this issue, provides a new molecular tool. The Na ϩ -Ca 2ϩ exchanger gene (NCX1) has three alternative promoters that are used in a tissue-specific manner. 7, 8 One of these promoters is responsible for expression of the exchanger in the myocardium as indicated by previous biochemical and in vitro analyses. Müller et al 6 create a mouse model to study exchanger expression using a transgene composed of the cardiac-specific promoter of NCX1 linked to a luciferase reporter gene. The transgenic mouse can then be used in a relatively simple manner to quantitate promoter activity. This should be of substantial utility because many reports in the literature document changes in exchanger expression in response to pathophysiological, pharmacological, and hormonal interventions. The study also suggests the possible use of the NCX1 heart promoter for the expression and analysis of other transgenes where early cardiacrestricted expression is desired.
Müller et al 6 use this transgenic mouse to study activity of the cardiac-specific promoter during development and during the onset of hypertrophy. In development, NCX1 expression is limited to the heart at early stages (up to day 14 postcoitum) but then occurs in other tissues. Müller et al 6 found that luciferase RNA is restricted to the heart throughout development, indicating the absolute tissue specificity of the cardiac promoter. After transaortic constriction of adult transgenic mice to induce hypertrophy (7 days), cardiac luciferase activity was upregulated by 2-fold, consistent with the upregulation of NCX protein as indicated by Western blots.
These initial studies demonstrate the usefulness of these transgenic mice to study exchanger expression. Two caveats are necessary: First, it is possible (although unlikely) that alternative promoters become active in the heart during interventions such as hypertrophy. Second, it would be prudent to carry out quantitative comparisons of expression of luciferase and exchanger protein and activity to learn whether luciferase expression truly parallels exchanger expression. Nevertheless, these promoter/luciferase transgenic mice hold great promise for future studies to determine the importance of various promoter elements and signal transduction pathways and also to monitor the effects of a variety of interventions on Na ϩ -Ca 2ϩ exchanger expression. The third tool involves the use of embryonic heart tubes from NCX1 knockout mice to study excitation-contraction coupling. This is described in a study 9 that was published online in Circulation Research (to appear in print in the next issue) and can be accessed using the journal's Online First feature. (This work is from the author's own laboratory. Lest the reader bristle at the obvious conflict of interest, be assured that inclusion of this citation was imposed by the Editor.) The article provides new information on the essential role of Na ϩ -Ca 2ϩ exchange in the action of cardiac glycosides. Taken together, the various new tools at our disposal promise to help us pinpoint the precise physiological role of the exchanger and how its function affects the diseased heart.
